Zymeworks Inc.
ZYME Real Time Price USDRecent trades of ZYME by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ZYME's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Methods of using a bispecific antigen-binding construct targeting her2 in combination with cdk4/6 inhibitors for the treatment of breast cancer Sep. 03, 2024
-
Patent Title: Engineered immunoglobulin heavy chain-light chain pairs and uses thereof Aug. 13, 2024
-
Patent Title: Bispecific antigen-binding constructs targeting her2 Apr. 23, 2024
-
Patent Title: Stabilized chimeric fabs Apr. 23, 2024
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of ZYME in WallStreetBets Daily Discussion
Recent insights relating to ZYME
Recent picks made for ZYME stock on CNBC
ETFs with the largest estimated holdings in ZYME
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ZYME Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.